Boston University
A self-assembling coiled-coil peptide platform for antibody-targeted therapeutics
Abstract
dc:description.abstractAntibody-drug conjugates (ADCs) have revolutionized cancer treatment, yet significant challenges limit their therapeutic potential and hamper their advancement to first-line treatments. Traditional conjugation methods lack stability, site-specificity and spatial control, resulting in heterogeneous products with compromised pharmacokinetics, efficacy, and safety profiles. This thesis presents a platform for advancing ADC technology through developing a novel peptide-based conjugation strategy and expands it to diverse payloads to create safe next-generation therapeutics. We first developed a supramolecular assembly conjugation method based on coiled-coil peptides to generate a robust site-specific ADC. This approach affords modular conjugation of multiple payloads. An ADC created via this platform demonstrated efficacy in human ovarian cancer xenograft model. Next, we developed a gram-scale synthetic scheme of a multifunctional cathepsin B-responsive linker that facilitates controlled drug release from antibodies. This scheme is high-yielding and avoids chromatographic purification, providing a pure product at the gram scale. Building on the coiled-coil conjugation platform, we demonstrated its modularity by expanding beyond traditional cytotoxic payloads to create antibody-enzyme conjugates that leverage enzymatic activity for metastasis reduction. By conjugating DNase to a neutrophil targeting antibody, we ensured enzyme delivery to close proximity of neutrophil extracellular traps, thereby reducing lung metastatic burden in an orthotopic 4T1 metastatic breast cancer model. Finally, we introduced a "smart" ADC platform integrating tumor-targeting with novel Regulated Induced Proximity Targeting Chimeras (RIPTACs). This approach overcomes off-target toxicities by requiring both extracellular target recognition and intracellular target recognition, establishing safer, more selective antibody-based therapeutics. Collectively, this work provides a uniform toolbox for ADC engineering and introduces new concepts for designing next-generation antibody conjugates with alternative payloads and mechanisms of action.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Chemistry
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ringaci, Alina
- Advisor dc:contributor.advisor
-
- Grinstaff, Mark W
- ORCID dc:identifier.orcid
Subjects
dc:subject × 5Rights
dc:rights- Statement dc:rights
-
- Attribution 4.0 International
- Licence dc:rights.uri
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53607